226 filings
Page 4 of 12
8-K
wsoor7a b6n2ai
29 Oct 20
Regulation FD Disclosure
5:19pm
8-K
meepukb9d h3b
27 Oct 20
NeoGenomics Reports Revenue Growth of 20% to Record $125 Million
7:59am
8-K
6ksr lb9142kl
31 Jul 20
INVESTOR PRESENTATION July 2020
5:10pm
8-K
ef22znvp sqhrcoq
28 Jul 20
NeoGenomics Reports Revenue of $87 Million
8:18am
8-K
f82mtz7yyiggdr
20 Jul 20
NeoGenomics Announces Board Appointments
5:06pm
8-K
aqn9y0otvj6 xv6
23 Jun 20
Departure of Directors or Certain Officers
5:00pm
8-K
now9q6
3 Jun 20
Departure of Directors or Certain Officers
4:41pm
8-K
dg1 7rgkdj57
27 May 20
NeoGenomics Enters Strategic Collaboration with Inivata to Commercialize InVisionFirstĀ®-Lung Liquid Biopsy Test
5:08pm
8-K
ptmp jg25xq8dzigx51g
4 May 20
NeoGenomics Announces Pricing of Public Offerings of Common Stock and Convertible Senior Notes
5:18pm
8-K
vwvua3ecmrbwvk
30 Apr 20
NeoGenomics Announces Proposed Public Offerings of Common Stock and Convertible Senior Notes
12:00am
8-K
gtaqzh0z
28 Apr 20
NeoGenomics Reports 11% Revenue Growth to $106 Million
8:15am
8-K
ssw2v
17 Apr 20
Improving Patient Care 2019 Annual Report
4:55pm
8-K
d5pc565biz1l
9 Apr 20
NeoGenomics Provides COVID-19 Business Update
5:12pm
8-K
oq8vzp3
2 Mar 20
INVESTOR PRESENTATION February 2020
5:19pm
8-K
iul6tfxl
27 Feb 20
NeoGenomics Reports 40% Revenue Growth to $107 Million
8:09am
8-K
3gjqr0lj
11 Feb 20
Departure of Directors or Certain Officers
5:06pm
8-K
rcc9br75rxt1i jq
13 Jan 20
NeoGenomics Acquires Oncology Division from Human Longevity for $37 Million
4:50pm
8-K
6w8rx1 twi
2 Dec 19
Departure of Directors or Certain Officers
5:07pm
8-K
m6o8yx ne1e29zmeww7
31 Oct 19
INVESTOR PRESENTATION October 2019
12:00am
8-K
3lfw0nbb7egb z8be9
29 Oct 19
NeoGenomics Reports 51% Revenue Growth to $105 Million
7:38am